Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma

Current Opinion in Hematology

Volumn 15, Issue 6, 2008, Pages 612-617

  Solheim, Bjarte G ^a   Chetty, Rangini ^b   Oystein, Flesland ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b National Bioproducts Institute   (South Africa)

^c VESTRE VIKEN HOSPITAL TRUST   (Norway)

Author keywords

ABO; Adverse events; Compatibility; Pathogen reduction; Plasma transfusion; Transfusion associated acute lung injury

Indexed keywords

DETERGENT; LEUKOCYTE ANTIBODY; LIPID; NEUTRALIZING ANTIBODY; PLASMA PROTEIN; SOLVENT;

ALLERGY; BLEEDING; BLOOD CLOTTING TEST; BLOOD COMPATIBILITY; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COST EFFECTIVENESS ANALYSIS; DONOR SELECTION; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; LICENSING; MEDICAL ERROR; NUCLEIC ACID AMPLIFICATION; PATHOGENESIS; PLASMA; PLASMA TRANSFUSION; PLASMA VOLUME; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SAFETY; SCREENING; SOUTH AFRICA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT INDICATION; VIRUS DETECTION; VIRUS TRANSMISSION;

ABO BLOOD-GROUP SYSTEM; ADULT; BLOOD COMPONENT TRANSFUSION; COST-BENEFIT ANALYSIS; HUMANS; PLASMA;

EID: 55149111374     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32831366d3     Document Type: Review

References (34)

1. Whitaker BI, Sullivan M. The 2005 nationwide blood collection and utilization survey report. Washington, DC: Department of Health and Human services; 2006.
2. Diamond LK. A history of blood transfusion. In: Wintrobe MM, editor. Blood, pure and eloquent. New York: McGraw-Hill; 1980. pp. 659-688.
3. Janeway CA. Plasma, the transport fluid for blood cells and humors. In: Wintrobe MM, editor. Blood, pure and eloquent. New York: McGraw-Hill; 1980. pp. 573-599.
4. Solheim BG. Universal pathogen-reduced plasma in elective open-heart surgery and liver resection [Review]. Clin Med Res 2006; 4:209-217. This review summarizes current European clinical studies.
5. HMSO. Dried human plasma. London: HMSO; 1973.
6. Heal JM, Blumberg N. The second century of ABO: and now for something completely different [Editorial]. Transfusion 1999; 39:1155-1159.
7. Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives. 1. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combination. Transfusion 1985; 25:516-522.
8. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma. A virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79:826-833.
9. Hellstem P, Sachse H, Schwinn H, Oberefrank K. Manufacture and in-vitro characterization of a solvent/detergent-treated plasma. Vox Sang 1992; 63:178-185.
10. Beeck H, Hellstern P. In vitro characterization of solvent/detergent- treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998; 74 (Suppl 1):219-223.
11. Solheim BG, Cid J, Osselaer J-C. Pathogen reduction technologies. In: Lonzano M, Contreras M, Blajchman M, editors. Global perspectives in transfusion medicine. Bethesda, MD, USA: AABB Press; 2006. pp. 103-148.
12. Solheim BG, Rollag H, Svennevig JL, et al. Viral safety of solvent/detergent-treated plasma. Transfusion 2000; 40:84-90.
13. Hellstem P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004; 11:346-350.
14. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, et al. Are quality differences responsible for different adverse reactions reported for SD-plasma for USA and Europe? Transfus Med 2006; 16:266-275.
15. Solheim BG. Pathogen reduction of blood components [Review], Transfus Apher Sci 2008; 39:75-82.
16. Chapanduka ZC, Femandez-Costa FJ, Rochat C, Blyth DF. Comparative safety and efficacy of Bioplasma FDP versus single-donor fresh-dried plasma in cardiopulmonary bypass patients [Letter]. S Afr Med J 2002; 92:356-357.
17. Rochat C, Larkin PM. Determination of portions of ABO blood groups in manufacture of Bioplasma FDP: a universal plasma? [Abstract]. Vox Sang 2006; 91 (Suppl 3):P-474.
18. Schleef M, Strobel E, Dick A. Relationship between ABO and secretor gen otype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 2005; 128:100-107.
19. Heger A, Römisch J, Svae T-E. A biochemical comparison of a pharmacologically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye an white-light treatment. Transfus Apher Sci 2006; 35:223-233. The study gives a detailed in-vitro and biochemical comparison of solvent detergent pathogen-reduced ABO blood group-specific and ABO-universal plasma.
20. Heger A, Römisch J, Nydegger U, et al. Rasma pools and transfusion plasma contain normal concentrations of soluble immune complexes [Abstract]. Transfus Altem Transfus Med 2007; 9 (Suppl):31.
21. Noddeland H, Tølløfsrud S, Svennevig JL, et al. Universal solvent/detergent-treated fresh frozen plasma (Uniplas®): rationale and clinical properties. Thromb Res 2002; 107:S33-S37.
22. Tollofsrud S, Noddeland H, Svennevig JL, et al. Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intensive Care Med 2003; 29:1736-1743.
23. Solheim BG, Granov DA, Juralev VA, et al. Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang 2005; 89:19-26.
24. Baele PL, De Bruyere M, Deneys V, et al. Bedside transfusion errors. A prospective survey by the Belgium Sanguis group. Vox Sang 1994; 66:117-121.
25. Fung MK, Downes KA, Shulman IA. Transfusion of platelets containing ABO-incompatible plasma. A survey of 3156 North American Laboratories. Arch Pathol Lab Med 2007; 131:909-916.
26. International Forum. Transfusion of platelets and ABO groups. Vox Sang 2005;88:207-221.
27. Solheim BG, Seghatchian J. Pathogen inactivation. In: Simon TI, Snyder EL, Solheim BG, et al. editors. Rossi's principles of transfusion medicine. 4th ed. Oxford, UK: Blackwell Publishing 2009: 801-810. Up-to-date presentation of pathogen reduction technologies.
28. Hellstem P. Fresh-frozen plasma, pathogen-reduced single donor plasma or biopharmaceutical plasma? Transfus Apher Sci 2008; 39:69-74. The study compares in-vitro and biochemical quality of the different types of plasma.
29. Scully M, Longair I, Flynn M, et al. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic pupura. Vox Sang 2007; 93:153-158. The study documents the safety of pathogen-reduced pooled plasma.
30. Bux J. Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox Sang 2005; 89:1-10.
31. Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med 2007; 33 (Suppl 1):S17-S21.
32. Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003; 85:88-95.
33. Shander A, Hofman A, Gombotz H, et al. Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007; 21:271-289. The study presents and discusses nonproduction-related costs of blood transfusion.
34. Olsson ML, Clausen H. Modifying the red cell surface: towards an ABO-universal blood supply. Br J Haematol 2007; 140:3-12. The study presents the significantly improved conditions for preparation of ABO-universal red blood cells.